Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare AI stocks to buy now. On December 12, TD Cowen reaffirmed a Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept a $115 price target. The firm went a step further to name Boston Scientific their “Best Idea for 2026.” TD Cowen Names Boston Scientific (BSX) Top 2026 Pick, Reaffirms Buy Image: Courtesy of Boston Scientific TD Cowen called Boston Scientific “the most attractive growth story in the medical devices sector.” The ...

As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRA TECHNOLOGIES OXY B.H.N.LTD. (Exact name of registrant as specified in its charter) State of Israel 3841 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of DexCom, Inc. about a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products, which may have health implications for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to its glucose monitoring products, the G6 and G7, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability and accuracy, were allegedly overstated, and the company downplayed the severity of the issues related to the G7 devices [3]. Group 2: Legal and Financial Implications - The allegations suggest that DexCom is facing increased regulatory scrutiny and potential enforcement actions, which could lead to significant legal, reputational, and financial harm [3]. - The public statements made by DexCom were claimed to be materially false and misleading throughout the relevant period, which could impact investor confidence and stock performance [3]. Group 3: Class Action Participation - Shareholders who purchased shares of DXCM between January 8, 2024, and September 17, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff applications set for December 26, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to join [4].

Whales with a lot of money to spend have taken a noticeably bearish stance on Intuitive Surgical.Looking at options history for Intuitive Surgical (NASDAQ:ISRG) we detected 26 trades.If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 46% with bearish.From the overall spotted trades, 8 are puts, for a total amount of $592,362 and 18, calls, for a total amount of $1,256,190.What's The Price Target?Analyzing the Volume and O ...

Core Insights - Becton, Dickinson and Company (BDX) has announced a collaboration with the Institute for Immunology and Immune Health (I3H) to develop the BD FACSDiscover A8 Cell Analyzer, aimed at enhancing the understanding of the human immune system and supporting immune-mediated treatments [1][4] Collaboration Details - The partnership will conduct an immune profiling study involving 1,000 participants to analyze over 30 cellular functions in whole blood, focusing on how individual immune cells respond to drugs or diseases [1][9] - The study will utilize the BD FACSDiscover A8 Cell Analyzer and the BD Rhapsody System, along with BD's cell analysis instruments and software, to convert complex immune data into actionable insights [2][8] Market Performance - Following the announcement, BDX shares increased by 0.5%, with a 15.3% rise over the past six months, outperforming the industry growth of 4.9% and the S&P 500's increase of 16.3% [3] Strategic Implications - This collaboration reinforces BDX's commitment to advanced flow cytometry and immune profiling, enhancing its competitive position in the immunotherapy market by aligning with a leading academic institution [4][10] - The partnership aims to develop high-quality immune-based therapies, with the potential for peer-reviewed publications to validate BDX's technology and promote broader adoption in various research settings [9][10] Industry Outlook - The immunology market is projected to reach $108.40 billion by 2025, with a compound annual growth rate (CAGR) of 10.2% through 2034, driven by increasing healthcare spending and the prevalence of autoimmune disorders [11]

Core Viewpoint - Integer Holdings Corporation has faced significant challenges, leading to a reduction in its sales guidance for 2025 and a negative outlook for 2026, which has resulted in a substantial decline in its stock price [2][3]. Financial Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which is below prior expectations [2]. - The company anticipates net sales growth of –2% to 2% and organic sales growth of 0% to 4% for 2026 [2]. Product Performance - Management indicated that sales of three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower market adoption than forecasted [2]. - The Cardio & Vascular sales growth is expected to decelerate, primarily due to declines in the electrophysiology products, with this impact continuing into 2026 [2]. Stock Market Reaction - Following the announcement of the reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [3]. Legal Proceedings - A class action lawsuit has been filed alleging that Integer made materially false and misleading statements regarding its business and operations during the class period from July 25, 2024, to October 22, 2025 [4]. - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers [4].

Core Viewpoint - Medtronic plc is highlighted as a promising healthcare AI stock following the FDA's approval of its HUGO robotic-assisted surgery system, which is expected to enhance its competitive position in the surgical robotics market [1][2]. Group 1: FDA Approval and Market Impact - The FDA granted regulatory approval for Medtronic's HUGO robotic-assisted surgery system, marking the end of a lengthy development phase and enabling competition in the US surgical robotics market [2][3]. - The HUGO system is intended for minimally invasive urologic surgical procedures, including prostatectomy, nephrectomy, and cystectomy [3][4]. - Stifel anticipates that significant revenue contributions from the HUGO launch will not materialize until Medtronic's fiscal year 2027 [2]. Group 2: Clinical Study and Launch Strategy - The approval of the HUGO system followed positive outcomes from the Expand URO investigational device exemption clinical study, which is noted as the largest multi-center prospective IDE trial for multi-port robotic-assisted urologic surgery in the US [4]. - Medtronic plans a phased launch of the HUGO system, focusing on partnerships with leading hospitals to facilitate its introduction into the market [4]. Group 3: Company Overview - Medtronic plc develops and manufactures a range of medical devices and therapies across various sectors, including cardiovascular, diabetes, surgical, and neurological care [5]. - The company's AI-enabled product portfolio includes GI Genius, Touch Surgery Enterprise for surgical video analysis, AiBLE for neurosurgery, and the MiniMed 780G insulin pump [5].

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best healthcare AI stocks to buy now. On December 16, David Rescott from Robert W. Baird reaffirmed a Buy rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) and maintained the $655 price target. Earlier on December 11, Citi’s Joanne Wuensch assigned a Hold rating on the stock. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances In a different update, on December 10, Intuitive announced that the FDA had cleared its da Vinci Single Po ...

Core Insights - MiMedx Group, Inc. has entered into an exclusive agreement with Regen Lab USA LLC to distribute the RegenKit-Wound Gel in the United States, enhancing its wound care product offerings [1][2]. Company Developments - The RegenKit-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that effectively concentrates essential growth factors and nutrients while removing iron-laden red blood cells [2]. - This product is backed by multiple studies demonstrating its effectiveness in treating chronic wounds and is covered nationally by CMS and LCD for diabetic chronic wounds under HCPCS code G0465 [2]. Strategic Positioning - The addition of RegenKit is expected to complement MiMedx's existing wound care portfolio, providing a broader range of proven solutions for patients and healthcare professionals [3]. - The company anticipates that this agreement, along with the clarity on Local Coverage Determination (LCD) implementation effective January 1, 2026, will strengthen its competitive position as it enters the new year [3]. About Regen Lab USA LLC - Regen Lab USA LLC is a leader in autologous regenerative medicine, specializing in high-quality medical devices for cell therapies and the preparation of autologous PRP from patients' own blood [4]. About MiMedx - MiMedx is a pioneer in wound care, focusing on innovative solutions to help manage chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions [5].

Core Insights - Abbott has received FDA approval for its Volt PFA System to treat atrial fibrillation (AFib), with plans to begin commercial cases in the U.S. and expand in the EU following earlier CE Mark approval [1][2] - Approximately 12 million people in the U.S. over the age of 65 have AFib, a number expected to double in the next 20 years, highlighting the growing need for effective treatment options [1] - The Volt PFA System demonstrated strong safety and effectiveness in the VOLT-AF IDE study, which included 392 patients across multiple countries [2] Product Features - The Volt PFA System is designed to simplify AFib treatment by allowing physicians to map, pace, and ablate using a single catheter, enhancing workflow and efficiency [4][5] - Its unique balloon-in-basket design provides superior tissue contact and energy delivery, addressing limitations of earlier PFA systems [3][4] - The system allows for fewer therapy applications, which can lead to better patient outcomes and reduced risk of complications [7] Clinical Benefits - The Volt PFA System supports conscious sedation instead of general anesthesia, which can facilitate faster recovery times for patients undergoing ablation procedures [7][8] - It reduces exposure to radiation and minimizes hemolysis, making it a safer option for patients [7] - The system is clinically proven to achieve durable lesions with fewer pulses, enhancing the effectiveness of first-time procedures [6][7]